Evidence map›Paper›PMID 36446261›Full record

ReviewJournal of pharmaceutical and biomedical analysis2023

Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals.

Szabolcs Fekete, Catalin Doneanu, Balasubrahmayam Addepalli, Maissa Gaye, Jennifer Nguyen, Bonnie Alden, Robert Birdsall, Duanduan Han, Giorgis Isaac, Matthew Lauber

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of pharmaceutical and biomedical analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Szabolcs FeketeWaters Corporation, Geneva, Switzerland.
Catalin DoneanuWaters Corporation, Milford, MA, USA.
Balasubrahmayam AddepalliWaters Corporation, Milford, MA, USA.
Maissa GayeWaters Corporation, Milford, MA, USA.
Jennifer NguyenWaters Corporation, Milford, MA, USA.
Bonnie AldenWaters Corporation, Milford, MA, USA.
Robert BirdsallWaters Corporation, Milford, MA, USA.
Duanduan HanWaters Corporation, Milford, MA, USA.
Giorgis IsaacWaters Corporation, Milford, MA, USA.
Matthew LauberWaters Corporation, Milford, MA, USA. Electronic address: Matthew_Lauber@waters.com.
Waters (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid encapsulated messenger RNA (LNP mRNA) has garnered a significant amount of interest from the pharmaceutical industry and general public alike. This attention has been catalyzed by the clinical success of LNP mRNA for SARS-CoV-2 vaccination as well as future promises that might be fulfilled by the biotechnology pipeline, such as the in vivo delivery of a CRISPR/Cas9 complex that can edit patient cells to reduce levels of low-density lipoprotein. LNP mRNAs are comprised of various chemically diverse molecules brought together in a sophisticated intermolecular complex. This can make it challenging to achieve thorough analytical characterization. Nevertheless, liquid chromatography is becoming an increasingly relied upon technique for LNP mRNA analyses. Although there have been significant advances in all types of LNP mRNA analyses, this review focuses on recent developments and the possibilities of applying anion exchange (AEX) and ion pairing reversed phase (IP-RP) liquid chromatography for intact mRNAs as well as techniques for oligo mapping analysis, 5' endcap testing and lipid compositional assays.

Indexed as

COVID-19NanoparticlesChromatography, LiquidCOVID-19 VaccinesHumansLipidsPharmaceutical PreparationsRNA, MessengerSARS-CoV-2COVID-19 VaccinesLipidsPharmaceutical PreparationsRNA, MessengerAnion exchangeIon-pairing reversed phaseLipid compositional analysisLipid nanoparticlesmRNAOligo mapping

Identifiers

PMID36446261
PMCPMC9678211
OpenAlexW4309525922

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.